Approved Medications 2016



The following Medications have been new approved in 2016, by the Government. Review the the name of the Medication and its Indications.


                                 Newely Approved Medications
An injectable GLP-1 agonist for type 2 diabetes
Apremilast (Otezla)
A phosphodiesterase 4 (PDE4)
inhibitor for psoriatic arthritis
Belinostat (Beleodaq)
A histone deacetylase
inhibitor for advanced peripheral T-cell lymphoma
Ceritinib (Zykadia)
A kinase inhibitor for
treatment of certain type of metastatic non–small-cell lung cancer
Cobicistat (Tybost)
Pharmaco-enhancing or
“boosting” agent for antiviral drugs used in treatment of HIV infection
Dalbavancin (Dalvance)
Antibiotic for treatment of
adult patients with complicated skin and skin structure infections, including
Dapagliflozin (Farxiga)
A sodium glucose co-transporter
2 (SGLT-2) inhibitor for type 2 diabetes
Droxidopa (Northera)
A synthetic amino acid
analogue for neurogenic orthostatic hypotension
Dulaglutide (Trulicity)
A glucagon-like peptide
receptor agonist for the treatment of type 2 diabetes
Elvitegravir (Vitekta)
Integrase inhibitor for
treatment of HIV-1 infection
Empagliflozin (Jardiance)
An SGLT-2 inhibitor for type 2
Idelalisib (Zydelig)
A kinase inhibitor for
treatment of chronic lymphocyticleukemia, relapsed follicular B-cell non-Hodgkin’s
lymphoma, and relapsed small lymphocytic lymphoma
Metreleptin (Myalept)
A leptin analogue for patients
with lipodystrophy
Naloxegol (Movantik)
A peripherally acting opioid
receptor antagonist indicated for the treatment of opioid-induced constipation
Olodaterol (StriverdiRespimat)
A long-acting beta agonist
oral inhaler for COPD
Oritavancin (Orbactiv)
An injectable lipoglycopeptide
antibiotic for skin and skin structure infections
Peginterferon beta-1a (Plegridy)
An interferon beta for
treatment of relapsing forms of multiple sclerosis
Pembrolizumab (Keytruda)
A human PD1-blocking antibody
indicated for the treatment of metastatic melanoma
Ramucirumab (Cyramza)
An angiogenesis inhibitor for
gastric cancer
Suvorexant (Belsomra)
An orexin receptor antagonist
indicated for the treatment of insomnia
Tedizolid (Sivextro)
An antibiotic for skin
Umeclidinium (Incruse Ellipta)
New anticholinergic oral
inhaler for maintenance treatment of COPD
Vedolizumab (Entyvio)
An integrin receptor
antagonist for treatment of Crohn’s disease and ulcerative colitis
Vorapaxar (Zontivity)
An antiplatelet agent for pts
with history of MI or with peripheral arterial disease (PAD)


Leave a Reply